Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inflammation and Cardiovascular Disease: The Future.
Arnold N, Lechner K, Waldeyer C, Shapiro MD, Koenig W. Arnold N, et al. Among authors: waldeyer c. Eur Cardiol. 2021 May 17;16:e20. doi: 10.15420/ecr.2020.50. eCollection 2021 Feb. Eur Cardiol. 2021. PMID: 34093741 Free PMC article. Review.
Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.
Waldeyer C, Makarova N, Zeller T, Schnabel RB, Brunner FJ, Jørgensen T, Linneberg A, Niiranen T, Salomaa V, Jousilahti P, Yarnell J, Ferrario MM, Veronesi G, Brambilla P, Signorini SG, Iacoviello L, Costanzo S, Giampaoli S, Palmieri L, Meisinger C, Thorand B, Kee F, Koenig W, Ojeda F, Kontto J, Landmesser U, Kuulasmaa K, Blankenberg S. Waldeyer C, et al. Eur Heart J. 2017 Aug 21;38(32):2490-2498. doi: 10.1093/eurheartj/ehx166. Eur Heart J. 2017. PMID: 28449027 Free PMC article.
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leiherer A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hoefer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS; GENIUS-CHD consortium; Krämer BK, Scharnagl H, Flis… See abstract for full author list ➔ Zewinger S, et al. Among authors: waldeyer c. Lancet Diabetes Endocrinol. 2017 Jul;5(7):534-543. doi: 10.1016/S2213-8587(17)30096-7. Epub 2017 May 26. Lancet Diabetes Endocrinol. 2017. PMID: 28566218 Free PMC article.
Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium.
Brunner FJ, Waldeyer C, Ojeda F, Salomaa V, Kee F, Sans S, Thorand B, Giampaoli S, Brambilla P, Tunstall-Pedoe H, Moitry M, Iacoviello L, Veronesi G, Grassi G, Mathiesen EB, Söderberg S, Linneberg A, Brenner H, Amouyel P, Ferrières J, Tamosiunas A, Nikitin YP, Drygas W, Melander O, Jöckel KH, Leistner DM, Shaw JE, Panagiotakos DB, Simons LA, Kavousi M, Vasan RS, Dullaart RPF, Wannamethee SG, Risérus U, Shea S, de Lemos JA, Omland T, Kuulasmaa K, Landmesser U, Blankenberg S; Multinational Cardiovascular Risk Consortium. Brunner FJ, et al. Among authors: waldeyer c. Lancet. 2019 Dec 14;394(10215):2173-2183. doi: 10.1016/S0140-6736(19)32519-X. Epub 2019 Dec 3. Lancet. 2019. PMID: 31810609 Free PMC article.
Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project.
Rothenbacher D, Rehm M, Iacoviello L, Costanzo S, Tunstall-Pedoe H, Belch JJF, Söderberg S, Hultdin J, Salomaa V, Jousilahti P, Linneberg A, Sans S, Padró T, Thorand B, Meisinger C, Kee F, McKnight AJ, Palosaari T, Kuulasmaa K, Waldeyer C, Zeller T, Blankenberg S, Koenig W; BiomarCaRE consortium. Rothenbacher D, et al. Among authors: waldeyer c. BMC Med. 2020 Nov 9;18(1):300. doi: 10.1186/s12916-020-01776-7. BMC Med. 2020. PMID: 33161898 Free PMC article.
Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target population.
Blaum C, Brunner FJ, Kröger F, Braetz J, Lorenz T, Goßling A, Ojeda F, Koester L, Karakas M, Zeller T, Westermann D, Schnabel R, Blankenberg S, Seiffert M, Waldeyer C. Blaum C, et al. Among authors: waldeyer c. Eur J Prev Cardiol. 2021 Apr 10;28(2):152–158. doi: 10.1177/2047487319885458. Epub 2019 Nov 10. Eur J Prev Cardiol. 2021. PMID: 33838040 Free article.
Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project.
Rehm M, Rothenbacher D, Iacoviello L, Costanzo S, Tunstall-Pedoe H, Fitton CA, Söderberg S, Hultdin J, Salomaa V, Jousilahti P, Palosaari T, Kuulasmaa K, Waldeyer C, Schnabel RB, Zeller T, Blankenberg S, Koenig W; BiomarCaRE Consortium. Rehm M, et al. Among authors: waldeyer c. ESC Heart Fail. 2022 Feb;9(1):57-65. doi: 10.1002/ehf2.13699. Epub 2021 Nov 26. ESC Heart Fail. 2022. PMID: 34825788 Free PMC article.
Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial.
Bauer A, Sappler N, von Stülpnagel L, Klemm M, Schreinlechner M, Wenner F, Schier J, Al Tawil A, Dolejsi T, Krasniqi A, Eiffener E, Bongarth C, Stühlinger M, Huemer M, Gori T, Wakili R, Sahin R, Schwinger R, Lutz M, Luik A, Gessler N, Clemmensen P, Linke A, Maier LS, Hinterseer M, Busch MC, Blaschke F, Sack S, Lennerz C, Licka M, Tilz RR, Ukena C, Ehrlich JR, Zabel M, Schmidt G, Mansmann U, Kääb S, Rizas KD, Massberg S; SMART-MI-DZHK9 investigators. Bauer A, et al. Lancet Digit Health. 2022 Feb;4(2):e105-e116. doi: 10.1016/S2589-7500(21)00253-3. Lancet Digit Health. 2022. PMID: 35090674 Free article. Clinical Trial.
[Cost-benefit analysis of new lipid-lowering agents].
Blaum C, Arnold N, Waldeyer C. Blaum C, et al. Among authors: waldeyer c. Herz. 2022 Jun;47(3):236-243. doi: 10.1007/s00059-022-05116-8. Epub 2022 Apr 25. Herz. 2022. PMID: 35467096 Review. German.
51 results